China Regenerative Medicine International Limited (8158.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$0.246 (+11.82%) as of
Key statistics
- Market cap
- 74.85M
- P/E (TTM)
- 2.73
- EPS (TTM)
- 0.090
- Dividend yield
- 0.00%
- 52-week range
- 0.180 – 0.660
- Beta
- -0.96
- Revenue (TTM)
- 86.4M
- Profit margin
- 31.87%
- Volume
- 35.00k
About China Regenerative Medicine International Limited
China Regenerative Medicine International Limited, together with its subsidiaries, engages in the research, development, production, and sale of tissue engineering and regenerative medicine products in Hong Kong and China. It operates in two segments, Aesthetic Medical and Beauty Services, and Medical Services. The company offers anti-aging /prevention, functional medicine and solutions, and treatment and diagnosis; hair regenerating medical solutions; and zoom consultation, mental fog therapy, physiotherapy, acnes treatment, and facial and slimming acupuncture services. It also provides skin regeneration, body function refining, Chinese/medical aesthetics, slimming and detoxing, and uterine and circulation services; endoscopy and scar removal services; and medical tests and vaccines. The company was formerly known as China Bio-Med Regeneration Technology Limited and changed its name to China Regenerative Medicine International Limited in February 2015. China Regenerative Medicine International Limited was founded in 1995 and is headquartered in Tsim Sha Tsui, Hong Kong.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Tsim Sha Tsui, Hong Kong
- Employees
- 33
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.